WO2021232714A1 - 一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒 - Google Patents
一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒 Download PDFInfo
- Publication number
- WO2021232714A1 WO2021232714A1 PCT/CN2020/129718 CN2020129718W WO2021232714A1 WO 2021232714 A1 WO2021232714 A1 WO 2021232714A1 CN 2020129718 W CN2020129718 W CN 2020129718W WO 2021232714 A1 WO2021232714 A1 WO 2021232714A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- novel coronavirus
- enzyme
- labeled
- fitc
- antigen
- Prior art date
Links
- 241000711573 Coronaviridae Species 0.000 title claims abstract description 65
- 238000002965 ELISA Methods 0.000 title claims abstract description 17
- 238000012360 testing method Methods 0.000 title abstract description 33
- 239000000427 antigen Substances 0.000 claims abstract description 36
- 102000036639 antigens Human genes 0.000 claims abstract description 36
- 108091007433 antigens Proteins 0.000 claims abstract description 36
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims abstract description 29
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000006243 chemical reaction Methods 0.000 claims abstract description 11
- 238000001514 detection method Methods 0.000 claims description 29
- 239000000243 solution Substances 0.000 claims description 27
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000872 buffer Substances 0.000 claims description 17
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000008157 ELISA kit Methods 0.000 claims description 11
- 238000000502 dialysis Methods 0.000 claims description 11
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 10
- 229920001184 polypeptide Polymers 0.000 claims description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 8
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 238000002372 labelling Methods 0.000 claims description 7
- 230000004913 activation Effects 0.000 claims description 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 239000012089 stop solution Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 3
- 241000872931 Myoporum sandwicense Species 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 239000002274 desiccant Substances 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- 239000011888 foil Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000012916 chromogenic reagent Substances 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 2
- 239000002953 phosphate buffered saline Substances 0.000 claims 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 239000006210 lotion Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000013039 cover film Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010035664 Pneumonia Diseases 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 238000013211 curve analysis Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 238000013461 design Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 230000002779 inactivation Effects 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000025721 COVID-19 Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241001109669 Human coronavirus HKU1 Species 0.000 description 1
- 241000482741 Human coronavirus NL63 Species 0.000 description 1
- 241001428935 Human coronavirus OC43 Species 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Definitions
- the invention belongs to the technical field of immunoassay detection, and particularly relates to an enzyme-linked immunoassay detection kit for a novel coronavirus IgM antibody.
- Coronaviruses are single-stranded positive-stranded RNA viruses.
- the new coronavirus (2019-nCoV) belongs to the seventh category.
- coronavirus pneumonia is an acute infectious pneumonia, and its pathogen is a new type of coronavirus that has not been previously found in humans, that is, the 2019 new type of coronavirus.
- Spread through respiratory droplets and close contact are the main routes of transmission, and it is possible to spread through aerosols when exposed to high concentrations of aerosols for a long time in a relatively closed environment.
- the initial symptoms of the patients were mostly fever, fatigue and dry cough, and gradually developed severe symptoms such as dyspnea. Most patients have a good prognosis, and some severe cases can develop acute respiratory distress syndrome or septic shock, or even die.
- nucleic acid testing must be carried out in qualified and qualified laboratories.
- There are shortcomings such as long testing time, high sample collection requirements, multiple steps, high site and equipment requirements, and it is difficult to carry out large-scale testing.
- the use of immunoassay for antibody detection can be used to screen high-risk populations.
- IgM can be used for clinical auxiliary diagnosis or epidemiological monitoring of primary infection of novel coronavirus pneumonia in the middle and late stages. How to achieve this clinical auxiliary diagnosis has become an urgent need to solve The problem.
- the present invention aims to provide an enzyme-linked immunosorbent assay kit for the new type of coronavirus IgM antibody, which has simple operation, fast speed, low cost, and low laboratory requirements compared with the existing nucleic acid detection kits.
- An enzyme-linked immunosorbent assay kit for a novel coronavirus IgM antibody including an anti-FITC antibody enzyme-labeled plate, FITC-labeled novel coronavirus antigen, and horseradish peroxidase-labeled mouse anti-human IgM monoclonal antibody.
- the novel coronavirus antigen in the FITC-labeled novel coronavirus antigen includes four synthetic polypeptides as shown in Table 1 or a recombinant antigen that includes the amino acid sequences of the four synthetic polypeptides as shown in Table 1.
- novel coronavirus antigen in the FITC-labeled novel coronavirus antigen may have an amino acid sequence as shown in Table 2:
- the mass ratio of the 4 synthetic polypeptides is (0.5-2): (0.5-2): (0.5-2): (0.5-2); preferably, 1 :1:1:1.
- the preparation of the FITC-labeled novel coronavirus antigen includes the following steps:
- step 2) Dialysis the labeling solution completed in step 2) above with 0.01-0.05M PBS at 2-8°C for 24 hours, add an equal volume of glycerol, and store at -20°C.
- the stop solution is one of concentrated sulfuric acid, hydrochloric acid, and sodium hydroxide.
- it also includes a diluent; MES 2-5g/L; NaCl 2-10g/; BSA 5-20g/L; Dextran 2000 1-5g/L; Tween-20 1-5mL/L; ProClin TM 300 1-5mL/L; pH 8.0 ⁇ 0.20.
- MES 2-5g/L NaCl 2-10g/
- BSA 5-20g/L Dextran 2000 1-5g/L
- ProClin TM 300 1-5mL/L
- pH 8.0 ⁇ 0.20 a diluent
- the working concentrations of FITC-labeled novel coronavirus antigen and horseradish peroxidase-labeled mouse anti-human IgM monoclonal antibody are both 0.01-0.5 ⁇ g/mL.
- the preparation of the anti-FITC antibody ELISA plate includes the following steps: dilute the anti-FITC antibody with 0.02-0.05M phosphate buffer to 1-5 ⁇ g/mL, and add it to the transparent plastic ELISA plate at 2-8°C. Coating for 16-24 hours; discard the liquid in the well, wash the plate with pH 7.4 PBS buffer, and then add a phosphate buffer containing 0.5-2% BSA and 1-5% trehalose to seal the microwell plate. Seal at 2-8°C for 16-24 hours; discard the liquid in the hole, spin dry and dry at 37°C for 4-12 hours; put it into an aluminum foil bag, add desiccant, seal, label, and store at 2-8°C.
- the preparation method of horseradish peroxidase-labeled mouse anti-human IgM monoclonal antibody is as follows:
- HRP Horseradish peroxidase
- step 1) Mix the solution prepared in step 1) and step 2) at a volume ratio of 1:1, and react at 2-8°C in the dark for 0.5-2h;
- the anti-FITC antibody ELISA plate, the solid phase carrier of the ELISA plate is a 96-well or 48-well transparent microtiter plate, and the average variation between wells is not higher than 10%.
- Functionality Matching with other qualified components can ensure the compliance rate of the negative reference product, the compliance rate of the positive reference product, the lowest detection limit, precision and stability of the 2019-nCoV IgM antibody determination. Store at 2 ⁇ 8°C.
- FITC labeling the new coronavirus antigen must meet (1) Appearance: clear, orange-yellow, without turbid precipitation. (2) Functionality: Matching with other qualified components can ensure the compliance rate of negative reference products, positive reference product compliance rate, minimum detection limit, precision and stability of the 2019-nCoV IgM antibody determination. Store at 2 ⁇ 8°C.
- Horseradish peroxidase labeled mouse anti-human IgM monoclonal antibody must meet (1) Appearance: clear and transparent, without turbid precipitation. (2) Functionality: Matching with other qualified components can ensure the compliance rate of negative reference products, positive reference product compliance rate, minimum detection limit, precision and stability of the 2019-nCoV IgM antibody determination. Store at 2 ⁇ 8°C.
- Enterprise reference products can be provided as needed, including negative reference products, positive reference products, minimum detection limit reference products, and precision reference products.
- Negative reference products 20 corporate negative reference products (N1-N20) shall be tested without false positives, and the compliance rate of negative reference products is 20/20.
- Preparation select 20 new coronavirus IgM antibody negative serum samples, which contain positive interference samples such as influenza A virus, influenza B virus, and Mycoplasma pneumoniae. After inactivation and dilution by a certain multiple, each aliquot is 0.5mL , Store at -20°C.
- test 10 corporate positive reference products (P1-P10) without false negatives, and the compliance rate of positive reference products is 10/10.
- P1-P10 corporate positive reference products
- the compliance rate of positive reference products is 10/10.
- the lowest detection limit reference product the company detection limit reference product L1-L4 should be tested, L1 and L2 should be tested as positive, L3 can be tested as positive or negative, and L4 should be tested as negative.
- L1-L4 The lowest detection limit reference product, the company detection limit reference product L1-L4 should be tested, L1 and L2 should be tested as positive, L3 can be tested as positive or negative, and L4 should be tested as negative.
- the kit should also include a negative control and a positive control reagent.
- the negative control is prepared by adding a buffer containing bovine serum albumin to ProClin TM 300 with a volume concentration of 1%. Divide, label, and store at 2 ⁇ 8°C.
- the formula of the buffer solution is: 5-15g/L BSA, 0.01-0.02mol/L PBS (pH value: 7-8, validity period: 14 months)
- Positive control, preparation method mix 5 positive human serums, heat-inactivate them at 56°C for 45 minutes, dilute them with a buffer containing bovine serum albumin to a suitable working concentration, add 1-5% ProClin TM 300 by volume, Divide, label, and store at 2 ⁇ 8°C.
- the formula of the buffer solution is: 5-15g/L BSA, 0.01-0.02mol/L PBS (PH value: 7-8, validity period: 14 months).
- a new type of coronavirus (2019-nCoV) IgM antibody detection kit (enzyme-linked immunoassay) of the present invention uses an enzyme-linked immunoassay (ELISA) measurement system, which consists of an immune response system and a microplate reader measurement system.
- ELISA enzyme-linked immunoassay
- microplate reader Use a microplate reader to read the OD value produced by the immunoreaction product and the chromogenic reagent to indicate the presence or absence of the immunoreactant and its content, so as to achieve the detection of the antigen or antibody substance content. It has the advantages of high sensitivity and strong specificity.
- This product uses the principle of indirect method to detect the new coronavirus IgM antibody in human serum. Add the FITC-labeled novel coronavirus recombinant antigen or synthetic peptide and sample to the reaction well of the ELISA plate. If the sample contains the novel coronavirus IgM antibody, it will form a complex with the synthetic polypeptide or recombinant antigen in the above reagents and bind to the package. On the quilt, wash away free components.
- horseradish peroxidase-labeled mouse anti-human IgM monoclonal antibody to the reaction tube, horseradish peroxidase-labeled mouse anti-human IgM monoclonal antibody is used as the secondary antibody, which binds to the IgM antibody in the sample to form horseradish Peroxidase labels the antibody-IgM antibody-complex to wash away free components.
- Chromogenic Solution A and Chromogenic Solution B and react at 37 ⁇ 1°C.
- Add stop solution select the microplate reader 450nm to detect the OD value.
- the novel coronavirus IgM enzyme immunoassay kit of the present invention has the following advantages:
- Figure 1 is a ROC curve analysis diagram of the embodiment
- test reagents used in the following examples are all conventional biochemical reagents; the experimental methods, unless otherwise specified, are all conventional methods.
- An enzyme-linked immunosorbent assay kit for novel coronavirus IgM antibody including anti-FITC antibody enzyme-labeled plate, FITC-labeled novel coronavirus antigen, horseradish peroxidase-labeled mouse anti-human IgM monoclonal antibody, corporate reference materials, negative Control, positive control, substrate solution, concentrated lotion, physiological saline, reaction tube.
- the preparation method of the anti-FITC antibody ELISA plate is as follows: dilute the anti-FITC antibody to 1 ⁇ 5 ⁇ g/mL with 0.02M phosphate buffer solution, and add it to the 96-well transparent plastic ELISA plate at the same time, and coat at 2-8°C for 16- 24 hours; discard the liquid in the well, wash the plate with pH 7.4 PBS buffer, then add 0.5-5% BSA, 2-5% trehalose-containing phosphate buffer to block the microwell plate, and block at 2-8°C 16 -24 hours; discard the liquid in the hole, dry it and dry it at 37°C for 20-24 hours; put it into an aluminum foil bag, add desiccant, seal, label, and store at 2-8°C.
- the novel coronavirus antigen is 4 kinds of synthetic peptides mixed at the same mass ratio; the amino acid sequences of the 4 kinds of synthetic peptides are shown below,
- FITC-labeled novel coronavirus synthetic polypeptide used in this application can be synthesized by the above method, or can be synthesized by other existing conventional methods, as long as it can achieve the connection of FITC and the novel coronavirus synthetic polypeptide.
- the 20-fold concentrated lotion includes 58g/L disodium hydrogen phosphate, 5.92g/L sodium dihydrogen phosphate, 180g/L NaCl, 10 mL/L Tween-20 and 2% Proclin300 by mass concentration.
- Negative control and positive control reagents including the negative control, the preparation method: add the buffer containing bovine serum albumin to 1% volume concentration of ProClin TM 300. Divide, label, and store at 2 ⁇ 8°C.
- the formula of the buffer solution is: 10g/L BSA, 0.02mol/L PBS (pH value: 7-8, validity period: 14 months)
- Positive control preparation method: mix 5 positive human serum, heat-inactivate at 56°C for 45 minutes, dilute to working concentration with buffer containing bovine serum albumin, add ProClinTM 300, subpackage, label, and store at 2 ⁇ 8°C.
- the formula of the buffer solution is: 10g/L BSA, 0.02mol/L PBS (pH value: 7-8, validity period: 14 months).
- the preparation of the diluent includes the following steps. In 1.7L process water, add 7.96g MES, 9g NaCl, and stir until completely dissolved; then add 20g BSA, 5g dextran 2000 and stir overnight until completely dissolved; then add 2.0mLTween-20, 4.0mL ProClinTM300, stirring for 30 minutes. Dilute the volume to 2L with purified water, measure the pH value with a pH meter, and adjust the pH value within the range of 8.0 ⁇ 0.20 with 6M HCl or 2M NaOH.
- the steps of the modified sodium periodate oxidation method include:
- HRP Horseradish peroxidase
- step 4) Dialysis the labeling solution completed in step 3) above with 0.01M PBS at 2-8°C for 24 hours, add an equal volume of glycerol, and store at -20°C.
- Liquid preparation Dilute the 20-fold concentrated lotion 1:20 with purified water (475mL purified water plus 25mL concentrated lotion). If there are crystals in the concentrated lotion, place the concentrated lotion at room temperature or 37°C for the crystals to dissolve before diluting.
- Sample processing Take 1mL of physiological saline, add 20 ⁇ L of sample, mix well, mix well with a vortex mixer for 5 seconds, and start the experiment after standing still for 15 minutes.
- microplate reader model HBS-1101
- manufacturer Nanjing Detie Experimental Equipment Co., Ltd.
- Test method Take out the kit after storing it at 37°C for 7 days, and test the enterprise reference product.
- the S/CO value is the OD value/cutoff value of the test sample.
- the ROC curve is used to determine the sensitivity and specificity of the kit under different cutoff values, and the optimal cutoff value is screened out, with a value of 0.1.
- the ROC curve analysis result shows that the area under the curve is 0.959, indicating that the kit of the present invention has high accuracy in clinical diagnosis.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
样本编号 | 性别 | 年龄 | 诊断 | OD | S/CO | IgM判断 | 核酸 |
EM-0031 | 女 | 40 | 排除 | 0.0476 | 0.48 | - | - |
EM-0034 | 女 | 48 | 排除 | 0.0173 | 0.17 | - | - |
EM-0059 | 女 | 17 | 排除 | 0.0090 | 0.09 | - | - |
EM-0060 | 男 | 54 | 排除 | 0.0361 | 0.36 | - | - |
EM-0072 | 男 | 33 | 排除 | 0.0280 | 0.28 | - | - |
EM-0073 | 男 | 33 | 排除 | 0.0171 | 0.17 | - | - |
EM-0132 | 女 | 29 | 排除 | 0.0826 | 0.83 | - | - |
EM-0133 | 女 | 25 | 排除 | 0.0566 | 0.57 | - | - |
EM-0193 | 女 | 5 | 排除 | 0.0999 | 1.00 | - | - |
EM-0194 | 男 | 43 | 排除 | 0.0372 | 0.37 | - | - |
EM-0215 | 女 | 3 | 排除 | 0.0922 | 0.92 | - | - |
EM-0216 | 女 | 60 | 排除 | 0.0121 | 0.12 | - | - |
EM-0228 | 男 | 76 | 排除 | 0.0228 | 0.23 | - | - |
EM-0230 | 女 | 13 | 排除 | 0.0910 | 0.91 | - | - |
EM-0293 | 女 | 27 | 排除 | 0.0184 | 0.18 | - | - |
EM-0294 | 女 | 1 | 排除 | 0.0304 | 0.30 | - | - |
EM-0324 | 男 | 65 | 排除 | 0.0609 | 0.61 | - | - |
样本编号 | 性别 | 年龄 | 诊断 | 发光值 | S/CO | IgM判断 | 核酸 |
EM-0005 | 男 | 31 | 确诊 | 0.8223 | 8.22 | + | + |
EM-0006 | 男 | 30 | 确诊 | 0.6666 | 6.67 | + | + |
EM-0033 | 女 | 57 | 确诊 | 1.8572 | 18.57 | + | + |
EM-0035 | 女 | 58 | 确诊 | 1.6255 | 16.26 | + | + |
EM-0235 | 男 | 48 | 确诊 | 0.8928 | 8.93 | + | + |
EM-0236 | 女 | 34 | 确诊 | 1.5510 | 15.51 | + | + |
EM-0244 | 女 | 53 | 确诊 | 1.5025 | 15.03 | + | + |
EM-0246 | 女 | 60 | 确诊 | 0.3227 | 3.23 | + | + |
EM-0369 | 男 | 33 | 确诊 | 1.0774 | 10.77 | + | + |
EM-0371 | 女 | 32 | 确诊 | 1.9214 | 19.21 | + | + |
EM-0408 | 男 | 72 | 确诊 | 0.4456 | 4.46 | + | + |
EM-0410 | 女 | 43 | 确诊 | 0.4289 | 4.29 | + | + |
EM-0586 | 男 | 37 | 确诊 | 0.9151 | 9.15 | + | + |
EM-0656 | 女 | 60 | 确诊 | 0.4388 | 4.39 | + | + |
Claims (9)
- 一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒,其特征在于:包括抗FITC抗体酶标板、FITC标记新型冠状病毒抗原、辣根过氧化酶标记鼠抗人IgM单克隆抗体。
- 根据权利要求2所述的新型冠状病毒IgM抗体的酶联免疫法检测试剂盒,其特征在于:新型冠状病毒抗原包括4种合成多肽时,4种合成多肽的质量比为(0.5-2):(0.5-2):(0.5-2):(0.5-2)。
- 根据权利要求1~3任一项所述的新型冠状病毒IgM抗体的酶联免疫法检测试剂盒,其特征在于:所述FITC标记新型冠状病毒抗原的制备包括以下步骤,1)将新型冠状病毒抗原装入透析袋中,用0.02-0.1M pH8.5-10的碳酸盐缓冲液,透析1-2h,当新型冠状病毒抗原为合成多肽时,省略该步骤;2)当新型冠状病毒抗原为重组抗原时,将FITC与新型冠状病毒抗原按摩尔比(2-4):1进行混合,之后用0.02-0.1M碳酸盐缓冲液于2-8℃透析20-24h,期间换液2-3次;当使用新型冠状病毒合成多肽时,将FITC与合成多肽按摩尔比1:(1-3)进行混合,避光37℃反应6-12h;3)将上述步骤2)完成的标记液用0.01-0.05M PBS于2-8℃透析24h,加入等体积甘油,-20℃保存。
- 根据权利要求1所述的新型冠状病毒IgM抗体的酶联免疫法检测试剂盒,其特征在于:还包括TMB显色剂A液和B液、以及终止液;所述终止液为浓硫酸,盐酸,氢氧化钠中的一种。
- 根据权利要求1所述的新型冠状病毒IgM抗体的酶联免疫法检测试剂盒,其特征在于:还包括稀释液;MES 2-5g/L;NaCl 2-10g/L;BSA 5-20g/L;葡聚糖2000 1-5g/L;Tween-20 1-5mL/L;ProClin TM300 1-5mL/L;pH 8.0±0.20。
- 根据权利要求1所述的新型冠状病毒IgM抗体的酶联免疫法检测试剂盒,其特征在于:FITC标记新型冠状病毒抗原、辣根过氧化酶标记鼠抗人IgM单克隆抗体的工作浓度均为0.01~0.5μg/mL。
- 根据权利要求1所述的新型冠状病毒IgM抗体的酶联免疫法检测试剂盒,其特征在于:抗FITC抗体酶标板的制备包括如下步骤,将抗FITC抗体用0.02-0.05M磷酸盐缓冲液稀释至1~5μg/mL,同时加入到透明塑料酶标板中,2-8℃包被16-24小时;弃去孔内液体,用pH 7.4PBS缓冲液洗板,然 后加入含质量浓度0.5-2%BSA,1-5%的海藻糖的的磷酸盐缓冲液封闭微孔板,2-8℃封闭16-24小时;弃去孔内液体,甩干后于37℃烘干4-12小时;装入铝箔袋,加入干燥剂,封口,贴标签,储存于2~8℃。
- 根据权利要求1所述的新型冠状病毒IgM抗体的酶联免疫法检测试剂盒,其特征在于:辣根过氧化酶标记鼠抗人IgM单克隆抗体的制备方法如下,A:辣根过氧化物酶(HRP)活化1)配置5-10mg/mL HRP溶液;2)配置10-20mg/mL过碘酸钠NaIO 4溶液;3)将步骤1)和步骤2)配制溶液按体积比1:(1-3)混匀,2-8℃避光反应0.5-2h;4)配置浓度为10-40μL/mL的乙二醇水溶液,与步骤3)配制的溶液以相同体积混合,常温避光反应10-30min,活化即完成,放-20℃保存(保存时间不超过3个月);B、辣根过氧化物酶标记鼠抗人IgM单克隆抗体1)将待标记原料装入透析袋中,用0.02-0.1M pH8.5-10的碳酸盐缓冲液,透析0.5-2h;2)将标记原料与活化的HRP按质量比1:(1-5)进行混合,之后用0.02-0.1M碳酸盐缓冲液于2-8℃透析20-24h,期间换液2-3次;3)配置浓度为2-5mg/mL的NaBH 4水溶液,按1mgHRP加80μL配制好的NaBH 4水溶液的比例进行混合,并于2-8℃避光反应1-2h;4)将上述步骤3)完成的标记液用0.01-0.05M PBS于2-8℃透析20-24h,加入等体积甘油,-20℃保存。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010417201.7A CN111551715B (zh) | 2020-05-18 | 2020-05-18 | 一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒 |
CN202010417201.7 | 2020-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021232714A1 true WO2021232714A1 (zh) | 2021-11-25 |
Family
ID=71998902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/129718 WO2021232714A1 (zh) | 2020-05-18 | 2020-11-18 | 一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN111551715B (zh) |
WO (1) | WO2021232714A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111551715B (zh) * | 2020-05-18 | 2022-04-22 | 天津博奥赛斯生物科技股份有限公司 | 一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒 |
CN111337672B (zh) * | 2020-05-18 | 2020-09-08 | 博奥赛斯(天津)生物科技有限公司 | 一种新型冠状病毒IgG抗体的酶联免疫法检测试剂盒 |
CN112114141A (zh) * | 2020-09-11 | 2020-12-22 | 博奥赛斯(天津)生物科技有限公司 | 一种新型冠状病毒IgA抗体化学发光法检测试剂盒 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111122864A (zh) * | 2020-03-25 | 2020-05-08 | 中山生物工程有限公司 | 新型冠状病毒IgG抗体酶联免疫检测试剂盒及其检测方法 |
DE202020102077U1 (de) * | 2020-04-15 | 2020-05-11 | Protzek Gesellschaft für Biomedizinische Technik GmbH | Vorrichtung zur gezielten Prüfung auf eine erfolgte Infektion mit dem Coronavirus-SARS-CoV-2 |
CN111337672A (zh) * | 2020-05-18 | 2020-06-26 | 博奥赛斯(天津)生物科技有限公司 | 一种新型冠状病毒IgG抗体的酶联免疫法检测试剂盒 |
CN111551715A (zh) * | 2020-05-18 | 2020-08-18 | 博奥赛斯(天津)生物科技有限公司 | 一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒 |
WO2020172496A1 (en) * | 2019-02-21 | 2020-08-27 | Ding Qinxue | Method of removing non-specific binding signals using microparticles |
EP3715847A1 (en) * | 2020-02-20 | 2020-09-30 | Euroimmun Medizinische Labordiagnostika AG | A method and reagents for the diagnosis of sars-cov-2 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101377504A (zh) * | 2008-04-16 | 2009-03-04 | 北京科美东雅生物技术有限公司 | 一种检测弓形虫IgM抗体的化学发光免疫分析测定试剂盒 |
EP2885009A1 (en) * | 2012-08-20 | 2015-06-24 | Novassay SA | Cholyl-l-lysyl-fluorescein assay |
CN102914645A (zh) * | 2012-11-12 | 2013-02-06 | 武汉伊艾博科技有限公司 | 用于免疫吸附反应过程中抗体在固相载体上固定的方法 |
-
2020
- 2020-05-18 CN CN202010417201.7A patent/CN111551715B/zh active Active
- 2020-11-18 WO PCT/CN2020/129718 patent/WO2021232714A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020172496A1 (en) * | 2019-02-21 | 2020-08-27 | Ding Qinxue | Method of removing non-specific binding signals using microparticles |
EP3715847A1 (en) * | 2020-02-20 | 2020-09-30 | Euroimmun Medizinische Labordiagnostika AG | A method and reagents for the diagnosis of sars-cov-2 |
CN111122864A (zh) * | 2020-03-25 | 2020-05-08 | 中山生物工程有限公司 | 新型冠状病毒IgG抗体酶联免疫检测试剂盒及其检测方法 |
DE202020102077U1 (de) * | 2020-04-15 | 2020-05-11 | Protzek Gesellschaft für Biomedizinische Technik GmbH | Vorrichtung zur gezielten Prüfung auf eine erfolgte Infektion mit dem Coronavirus-SARS-CoV-2 |
CN111337672A (zh) * | 2020-05-18 | 2020-06-26 | 博奥赛斯(天津)生物科技有限公司 | 一种新型冠状病毒IgG抗体的酶联免疫法检测试剂盒 |
CN111551715A (zh) * | 2020-05-18 | 2020-08-18 | 博奥赛斯(天津)生物科技有限公司 | 一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒 |
Non-Patent Citations (2)
Title |
---|
HOFFMAN TOVE, NISSEN KAROLINA, KRAMBRICH JANINA, RöNNBERG BENGT, AKABERI DARIO, ESMAEILZADEH MOUNA, SALANECK ERIK, LINDAHL JO: "Evaluation of a COVID-19 IgM and IgG rapid test; an efficient tool for assessment of past exposure to SARS-CoV-2", INFECTION ECOLOGY & EPIDEMIOLOGY, vol. 10, no. 1, pages 1754538, XP055780765, DOI: 10.1080/20008686.2020.1754538 * |
ZHONG LING, CHUAN JUNLAN, GONG BO, SHUAI PING, ZHOU YU, ZHANG YI, JIANG ZHILIN, ZHANG DINGDING, LIU XIAOQI, MA SHI, HUANG YI, LIN : "Detection of serum IgM and IgG for COVID-19 diagnosis", SCIENCE CHINA LIFE SCIENCES, vol. 63, no. 5, 1 May 2020 (2020-05-01), China , pages 777 - 780, XP055870503, ISSN: 1674-7305, DOI: 10.1007/s11427-020-1688-9 * |
Also Published As
Publication number | Publication date |
---|---|
CN111551715B (zh) | 2022-04-22 |
CN111551715A (zh) | 2020-08-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021232712A1 (zh) | 新型冠状病毒igm/igg磁微粒化学发光免疫检测试剂盒 | |
WO2021232714A1 (zh) | 一种新型冠状病毒IgM抗体的酶联免疫法检测试剂盒 | |
WO2021232713A1 (zh) | 一种新型冠状病毒IgG抗体的酶联免疫法检测试剂盒 | |
CN111413496B (zh) | 一种新型冠状病毒IgM/IgG抗体化学发光法检测试剂盒 | |
CN108490166B (zh) | 一种改良实验缓冲液及其应用 | |
CN111337673B (zh) | 一种用于新型冠状病毒免疫检测的合成多肽组合物及应用 | |
WO2021169664A1 (zh) | 新型冠状病毒抗原及其检测用途 | |
CN101363853A (zh) | 人类免疫缺陷病毒抗原/抗体化学发光免疫分析测定试剂盒及其制备方法 | |
CN109900896A (zh) | 一种酶联免疫法检测试剂盒及其制备方法 | |
CN111474340B (zh) | 一种用于新型冠状病毒检测的酶标记的抗原、制备方法及试剂盒与应用 | |
CN101178404B (zh) | 人类免疫缺陷病毒抗体化学发光免疫分析诊断试剂盒及其制备方法 | |
CN110818800A (zh) | 一种通过构建桥连复合物间接检测目的分析物的检测方法 | |
CN105510580B (zh) | 一种检测发热伴血小板减少综合征病毒核衣壳蛋白特异性抗体的多肽‑酶联免疫吸附试剂盒 | |
WO2013146977A1 (ja) | 免疫分析方法及び試薬 | |
JPH03502248A (ja) | アッセイ用水性洗浄液、診断試験キット及び単純ヘルペスウイルスの測定方法 | |
EP0460097A1 (en) | Method and diagnostic test kit for detection of anti-cardiolipin | |
CN110045130A (zh) | 一种与IgA肾病相关的多肽的免疫分析检测试剂盒 | |
CN112710842B (zh) | hsCRP检测试剂盒和hsCRP的检测方法 | |
CN105974127A (zh) | 一种基于酶联免疫吸附技术的人中性粒细胞载脂蛋白异源二聚体定量装置 | |
CN105606816B (zh) | 一种检测发热伴血小板减少综合征病毒包膜糖蛋白特异性抗体的多肽‑酶联免疫吸附试剂盒 | |
CN206002550U (zh) | 一种人中性粒细胞载脂蛋白同源二聚体的定量装置 | |
CN112129933A (zh) | 一种免疫分析系统中抗生物素干扰的试剂、试剂盒及方法 | |
JPH09189698A (ja) | 免疫学的測定方法 | |
CN114544952A (zh) | 一种新型冠状病毒IgG型抗体ELISA定量检测试剂盒 | |
CN117247433A (zh) | 一种vp2蛋白抗原决定簇多肽、制备方法、基于该决定簇多肽的人库塔病毒检测方法及试剂盒 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20936120 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20936120 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 09.06.2023) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20936120 Country of ref document: EP Kind code of ref document: A1 |